Longevity Healthcare model basket

Medical Devices

A concentrated book of device platforms whose razor-and-blade economics are priced as one-off launches.

What is the thesis for Medical Devices?

We own the structural heart, surgical robotics, orthopedics, electrophysiology, and continuous glucose platforms whose installed bases generate high-margin consumables for a decade after the capital sale. The thesis rests on a simple observation: the sector has underperformed SPY badly over the trailing twelve months, and the drawdown compresses multiples on businesses whose recurring revenue profile is closer to software than to medtech.

This is a curated QuantLink model basket. It is not a filed portfolio, not a fund, and not investment advice.

Published Apr 14, 2026. Updated Apr 14, 2026. Source: QuantLink curated model basket and FastAPI ideas endpoint.

Holdings
10
Benchmark
SPY
Status
New
1Y model return
-25.3%

Performance as of Nov 22, 2026.

Thesis narrative

The question

Is the medical device platform universe priced as a cyclical capital-equipment basket exposed to hospital capex cycles and GLP-1 procedure substitution fears, or as a collection of razor-and-blade franchises whose installed bases produce 70-80% gross margin consumables on a ten-to-fifteen year utilization tail?

Base rates

The reference class is installed-base medical platforms across three prior cycles: cardiac rhythm management (1990-2010), minimally invasive surgery (2005-present), and continuous glucose monitoring (2016-present). In each case, the capital placement preceded consumable revenue by 12-24 months, consumables compounded at 12-18% annually for a decade after peak placements, and gross margins on the consumable stream ran 15-25 points above the capital. The equity base rate for diversified device baskets during installed-base harvest years has been roughly the 75th percentile of healthcare sub-sectors, with beta to hospital admissions near 0.4 and beta to SPY near 0.8.

The trailing-twelve-month data on this book is unambiguous: ABT is down roughly 21%, BSX down 32%, BAX down 37%, PODD down 21%, and DXCM down 7%. The SPX compounded a double-digit gain over the same window. Healthcare's underperformance is the setup, not a reason to stay away. The imputed expectation embedded in current multiples is that procedure volumes step down 8-12% and margins compress 200-300 basis points on a permanent basis. That is the bear case priced as a base case.

The reference class for a post-drawdown medtech entry is 2016-2017, when the basket de-rated on drug-pricing overhang and proceeded to compound above-market for the next four years once the narrative overhang cleared without the fundamentals deteriorating. Procedure volumes in structural heart, electrophysiology, and robotics are currently running above pre-pandemic trend, not below.

Why consensus is wrong

The sell-side has modeled GLP-1-driven procedure substitution as a linear subtraction from the surgical and orthopedic book. The emerging real-world evidence cuts the other way: GLP-1 patients remain on therapy for cardio-metabolic indications while presenting for elective joint replacement, cardiac ablation, and TAVR at rates that are flat-to-higher than the non-GLP-1 cohort because risk-adjusted surgical candidacy improves as weight comes off. The net effect on SYK's joints franchise, BSX's Watchman and Farapulse book, and EW's TAVR volumes is neutral-to-positive, not negative.

The second miss is the consumables arithmetic. ISRG places a da Vinci system once and sells instruments and accessories for the next ten years at roughly 70% gross margin. BSX placed Farapulse into the electrophysiology labs over 2024-2025; the consumable tail from that placement has not yet shown up in the income statement at scale. SYK's Mako robotic system is on the same curve. The market is extrapolating capital placement growth while ignoring that the consumable base is compounding off a larger installed footprint.

Third, DXCM and PODD are being priced as if GLP-1s reduce CGM and pump utilization. The Type 1 diabetes population is structurally separate from the GLP-1 addressable market, and the Type 2 intensive-insulin cohort that uses both categories is expanding, not contracting. The imputed substitution is not in the claims data.

Position construction

The book has four 20% anchors, a structural heart and CGM sleeve, and a small-cap optionality tail.

Installed-base anchors (~80%). ABT at ~20% is the CGM, structural heart, and diagnostics composite -- Libre is the highest-utilization consumable in the book and the multiple has compressed alongside the sector. ISRG at 20% is the purest razor-and-blade in medtech; instrument and accessory revenue per procedure is still expanding as fourth-generation platforms roll through the installed base. BSX at 20% is the electrophysiology and structural heart play after the worst drawdown in the book; Farapulse unit economics are only beginning to show up on a full-year basis. SYK at 20% is the orthopedic robotics and trauma franchise whose Mako-driven share shift in knees and hips runs for another five-plus years.

Structural heart and CGM extension (~16.2%). EW at ~7.7% is the TAVR pure-play that has held up on a trailing-year basis and whose EARLY TAVR expansion moves the addressable population meaningfully. DXCM at ~4.6% and PODD at ~3.9% are the continuous glucose and patch-pump franchises where GLP-1 fear has compressed multiples out of proportion to Type 1 and intensive-insulin volume trends.

Hospital essentials and optionality (~3.8%). BAX at ~2.1% is the hospital essentials and kidney care franchise at a distressed multiple after the worst trailing-year print in the book. TFX at ~1.0% is the interventional access and urology specialist mid-turnaround. TMDX at ~0.7% is the asymmetric position -- organ preservation and transport, the only position in the book with positive trailing-year performance and the only name whose addressable market is still sub-scale enough to compound above 25%.

Asymmetric payoff

If procedure volumes hold at current run-rate, consumable attach rates on the ISRG, BSX, and SYK installed bases continue to compound, and the GLP-1 substitution narrative resolves neutral-to-positive, the weighted book returns roughly 18-26% annualized over three years as multiples normalize. If hospital capex contracts sharply and procedure growth steps down 5-8%, the book returns roughly -5% to +5%. If Medicare site-of-service reimbursement shifts favor outpatient cardiac and orthopedic venues more aggressively than currently scheduled, the right tail is 30-45% with multiple expansion back to the 2021 band.

At 60% base, 25% bear, and 15% bull, expected value is roughly +13 to +18% annualized against an SPY base rate near +8%. The payoff is asymmetric because the trailing-year drawdown has already absorbed the bear-case multiple compression while the consumable tail on the installed base limits revenue damage even in a procedure down-cycle.

Three things that would change our mind

  1. CMS finalizing site-of-service neutrality in a form that cuts device reimbursement at the ASC and HOPD levels simultaneously, removing the cross-subsidy that supports outpatient procedure migration.
  2. Real-world claims data over two consecutive quarters showing GLP-1 initiation reduces orthopedic and cardiac procedure rates by more than 10% on a cohort-matched basis, confirming rather than refuting the substitution thesis.
  3. An ISRG fourth-generation cycle or BSX Farapulse rollout where consumable revenue per procedure declines on a same-installed-base basis -- the razor-and-blade relationship failing would invalidate the core framework.

What we're explicitly NOT betting on

We are NOT betting on a specific hospital capex recovery timeline; the consumables base compounds whether or not capital placements reaccelerate. We are NOT betting on any single product launch -- not a future da Vinci platform, not a specific BSX pipeline asset, not a Mako refresh. We are NOT betting on GLP-1 procedure substitution being zero; we are betting only that it is smaller than the multiple compression already reflects. We are NOT betting on a particular M&A outcome or a break-up of BAX. We are NOT betting on CGM reaching the non-diabetic wellness population at any specific penetration rate. The thesis requires only that procedure volumes stay near run-rate, consumable attach rates hold, and multiples normalize toward the trailing ten-year mean. Each is a weaker claim than picking the next platform winner, and the book is sized accordingly.

Model basket holdings

Model basket: curated equal or target weighting, not a filed portfolio. Weights are the target basket weights returned by the live ideas endpoint.

NameSymbolModel weight
Abbott LaboratoriesABT20.01%
Intuitive Surgical, Inc.ISRG20.00%
Boston Scientific CorporationBSX20.00%
Stryker CorporationSYK20.00%
Edwards Lifesciences CorporationEW7.69%
DexCom, Inc.DXCM4.59%
Insulet CorporationPODD3.94%
Baxter International Inc.BAX2.08%
Teleflex IncorporatedTFX0.99%
TransMedics Group, Inc.TMDX0.70%

Backtested performance vs SPY

Performance is backtested from the returned tearsheet series. It reflects the model basket methodology and benchmark series, not live fund returns or a filed portfolio track record. Performance as of Nov 22, 2026.

Total Return

-25.3%

↓ SPY +3.2%

Ann. Return

-26.2%

↓ SPY +3.3%

Ann. Vol

24.7%

↑ SPY 14.5%

Sharpe

-1.06

↓ SPY 0.23

Max Drawdown

-30.9%

↓ SPY -11.5%

Alpha vs SPY

-27.7%

↓ hit rate 40.5%

Performance as of Nov 22, 2026. Risk-free rate for Sharpe and Sortino: 0% (no risk-free rate applied).

Rolling Performance vs Benchmark

Portfolio Holdings

Holding
Weight
Country
Exchange
Sector
Industry
Mkt Cap
Price
1Y
1Y Trend
ABT
ABTAbbott Laboratories
20.0%
—
—
—
—
—
—
—
BSX
BSXBoston Scientific Corporation
20.0%
—
—
—
—
—
—
—
ISRG
ISRGIntuitive Surgical, Inc.
20.0%
—
—
—
—
—
—
—
SYK
SYKStryker Corporation
20.0%
—
—
—
—
—
—
—
EW
EWEdwards Lifesciences Corporation
7.7%
—
—
—
—
—
—
—
DXCM
DXCMDexCom, Inc.
4.6%
—
—
—
—
—
—
—
PODD
PODDInsulet Corporation
3.9%
—
—
—
—
—
—
—
BAX
BAXBaxter International Inc.
2.1%
—
—
—
—
—
—
—
TFX
TFXTeleflex Incorporated
1.0%
—
—
—
—
—
—
—
TMDX
TMDXTransMedics Group, Inc.
0.7%
—
—
—
—
—
—
—

SSR performance series fallback

The table below is the server-rendered reference series behind the interactive chart. Values show the wealth index level from a 1.00 starting value, not a second 1Y return figure. Series as of Nov 22, 2026.

DateModel basket wealth indexSPY
Nov 25, 20251.0000x1.0000x
Nov 26, 20250.9975x1.0069x
Nov 28, 20250.9989x1.0124x
Dec 1, 20250.9923x1.0078x
Dec 2, 20250.9823x1.0096x
Dec 3, 20250.9797x1.0131x
Dec 4, 20250.9794x1.0139x
Dec 5, 20250.9799x1.0158x
Dec 8, 20250.9562x1.0128x
Dec 9, 20250.9471x1.0119x
Dec 10, 20250.9525x1.0186x
Dec 11, 20250.9497x1.0210x
Dec 12, 20250.9517x1.0100x
Dec 15, 20250.9613x1.0085x
Dec 16, 20250.9581x1.0057x
Dec 17, 20250.9617x0.9946x
Dec 18, 20250.9648x1.0021x
Dec 19, 20250.9695x1.0083x
Dec 22, 20250.9763x1.0145x
Dec 23, 20250.9711x1.0192x
Dec 24, 20250.9725x1.0228x
Dec 26, 20250.9730x1.0227x
Dec 29, 20250.9699x1.0190x
Dec 30, 20250.9712x1.0178x
Dec 31, 20250.9637x1.0102x
Jan 2, 20260.9579x1.0121x
Jan 5, 20260.9654x1.0188x
Jan 6, 20260.9963x1.0249x
Jan 7, 20260.9975x1.0216x
Jan 8, 20260.9898x1.0215x
Jan 9, 20260.9883x1.0282x
Jan 12, 20260.9723x1.0298x
Jan 13, 20260.9616x1.0278x
Jan 14, 20260.9583x1.0227x
Jan 15, 20260.9504x1.0255x
Jan 16, 20260.9418x1.0247x
Jan 20, 20260.9413x1.0038x
Jan 21, 20260.9447x1.0154x
Jan 22, 20260.9240x1.0207x
Jan 23, 20260.9191x1.0211x
Jan 26, 20260.9270x1.0262x
Jan 27, 20260.9223x1.0303x
Jan 28, 20260.9172x1.0302x
Jan 30, 20260.9212x1.0251x
Feb 2, 20260.9153x1.0302x
Feb 3, 20260.9022x1.0215x
Feb 4, 20260.8676x1.0165x
Feb 5, 20260.8715x1.0039x
Feb 6, 20260.8744x1.0231x
Feb 9, 20260.8694x1.0280x
Feb 10, 20260.8751x1.0253x
Feb 11, 20260.8788x1.0251x
Feb 12, 20260.8629x1.0093x
Feb 13, 20260.8727x1.0100x
Feb 17, 20260.8842x1.0116x
Feb 18, 20260.8974x1.0167x
Feb 19, 20260.8895x1.0140x
Feb 20, 20260.8928x1.0213x
Feb 23, 20260.8982x1.0109x
Feb 24, 20260.8969x1.0183x
Feb 25, 20260.8999x1.0269x
Feb 26, 20260.9127x1.0212x
Feb 27, 20260.9149x1.0163x
Mar 2, 20260.9071x1.0168x
Mar 3, 20260.8969x1.0079x
Mar 4, 20260.8920x1.0150x
Mar 5, 20260.8803x1.0093x
Mar 6, 20260.8633x0.9961x
Mar 9, 20260.8748x1.0048x
Mar 10, 20260.8602x1.0032x
Mar 11, 20260.8544x1.0019x
Mar 12, 20260.8375x0.9867x
Mar 13, 20260.8305x0.9811x
Mar 16, 20260.8486x0.9911x
Mar 17, 20260.8552x0.9937x
Mar 18, 20260.8463x0.9799x
Mar 19, 20260.8377x0.9775x
Mar 20, 20260.8304x0.9608x
Mar 23, 20260.8275x0.9709x
Mar 24, 20260.8187x0.9676x
Mar 25, 20260.8225x0.9730x
Mar 26, 20260.8241x0.9557x
Mar 27, 20260.8063x0.9394x
Mar 30, 20260.7873x0.9362x
Mar 31, 20260.7950x0.9634x
Apr 1, 20260.7944x0.9707x
Apr 2, 20260.7933x0.9716x
Apr 6, 20260.7930x0.9762x
Apr 7, 20260.7900x0.9766x
Apr 8, 20260.8050x1.0015x
Apr 9, 20260.7948x1.0072x
Apr 10, 20260.7886x1.0066x
Apr 13, 20260.7999x1.0164x
Apr 14, 20260.8052x1.0288x
Apr 15, 20260.8056x1.0369x
Apr 16, 20260.7889x1.0395x
Apr 17, 20260.8037x1.0520x
Apr 20, 20260.7909x1.0499x
Apr 21, 20260.7670x1.0431x
Apr 22, 20260.7941x1.0536x
Apr 23, 20260.7937x1.0495x
Apr 24, 20260.7849x1.0577x
Apr 27, 20260.7788x1.0595x
Apr 28, 20260.7677x1.0543x
Apr 29, 20260.7463x1.0542x
Apr 30, 20260.7528x1.0646x
May 1, 20260.7396x1.0676x
May 4, 20260.7312x1.0637x
May 5, 20260.7289x1.0722x
May 6, 20260.7232x1.0871x
May 7, 20260.7301x1.0838x
May 8, 20260.7103x1.0927x
May 11, 20260.6916x1.0952x
May 12, 20260.7099x1.0936x
May 13, 20260.7077x1.0997x
May 14, 20260.7108x1.1084x
May 15, 20260.7077x1.0950x
May 18, 20260.7357x1.0943x
May 19, 20260.7440x1.0870x
May 20, 20260.7510x1.0981x
May 21, 20260.7449x1.1003x
May 22, 20260.7485x1.1046x
May 26, 20260.7459x1.1120x
May 27, 20260.7129x1.1118x
May 28, 20260.7123x1.1179x
May 29, 20260.7090x1.1207x
Jun 1, 20260.7067x1.1237x
Jun 2, 20260.6964x1.1253x
Jun 3, 20260.6981x1.1174x
Jun 4, 20260.7167x1.1216x
Jun 5, 20260.7198x1.0926x
Jun 8, 20260.7177x1.0951x
Jun 9, 20260.7326x1.0919x
Jun 10, 20260.7159x1.0747x
Jun 11, 20260.7118x1.0929x
Jun 12, 20260.7111x1.0989x
Jun 15, 20260.7115x1.1182x
Jun 16, 20260.7171x1.1116x
Jun 17, 20260.6942x1.0977x
Jun 18, 20260.7020x1.1062x
Jun 22, 20260.6909x1.1028x
Jun 23, 20260.7037x1.0868x
Jun 24, 20260.7054x1.0862x
Jun 25, 20260.7101x1.0878x
Jun 26, 20260.7221x1.0800x
Jun 29, 20260.7175x1.0977x
Jun 30, 20260.6987x1.1063x
Jul 1, 20260.7068x1.1048x
Jul 2, 20260.7371x1.1033x
Jul 6, 20260.7376x1.1130x
Jul 7, 20260.7414x1.1077x
Jul 8, 20260.7312x1.1043x
Jul 9, 20260.7284x1.1136x
Jul 10, 20260.7286x1.1184x
Jul 13, 20260.7271x1.1098x
Jul 14, 20260.6933x1.1138x
Jul 15, 20260.6991x1.1182x
Jul 16, 20260.7350x1.1121x
Jul 17, 20260.7074x1.1011x
Jul 20, 20260.7101x1.0994x
Jul 21, 20260.7010x1.1085x
Jul 22, 20260.6926x1.1072x
Jul 23, 20260.6946x1.0936x
Jul 24, 20260.7083x1.0947x
Jul 27, 20260.7274x1.0949x
Jul 28, 20260.7417x1.0975x
Jul 29, 20260.7440x1.0806x
Jul 30, 20260.7395x1.0988x
Jul 31, 20260.7358x1.1067x
Aug 3, 20260.7652x1.1224x
Aug 4, 20260.7595x1.1427x
Aug 5, 20260.7498x1.1404x
Aug 6, 20260.7594x1.1386x
Aug 7, 20260.7638x1.1455x
Aug 10, 20260.7808x1.1452x
Aug 11, 20260.7911x1.1415x
Aug 12, 20260.7929x1.1444x
Aug 13, 20260.7920x1.1524x
Aug 14, 20260.7866x1.1501x
Aug 17, 20260.7765x1.1447x
Aug 18, 20260.7794x1.1369x
Aug 19, 20260.7959x1.1393x
Aug 20, 20260.7695x1.1297x
Aug 21, 20260.7800x1.1344x
Aug 24, 20260.7723x1.1310x
Aug 25, 20260.7739x1.1346x
Aug 26, 20260.7648x1.1349x
Aug 27, 20260.7509x1.1423x
Aug 28, 20260.7601x1.1397x
Aug 31, 20260.7616x1.1363x
Sep 1, 20260.7519x1.1285x
Sep 2, 20260.7536x1.1335x
Sep 3, 20260.7439x1.1454x
Sep 4, 20260.7414x1.1410x
Sep 8, 20260.7039x1.1347x
Sep 9, 20260.7023x1.1294x
Sep 10, 20260.6937x1.1227x
Sep 11, 20260.6946x1.1322x
Sep 14, 20260.7121x1.1272x
Sep 15, 20260.7075x1.1220x
Sep 16, 20260.7143x1.1171x
Sep 17, 20260.7103x1.1297x
Sep 18, 20260.7114x1.1284x
Sep 21, 20260.7158x1.1459x
Sep 22, 20260.7222x1.1457x
Sep 23, 20260.7158x1.1375x
Sep 24, 20260.7100x1.1365x
Sep 25, 20260.7115x1.1427x
Sep 28, 20260.7165x1.1342x
Sep 29, 20260.7174x1.1321x
Sep 30, 20260.7085x1.1298x
Oct 1, 20260.6998x1.1318x
Oct 2, 20260.6966x1.1402x
Oct 5, 20260.7132x1.1479x
Oct 6, 20260.7037x1.1542x
Oct 7, 20260.7039x1.1514x
Oct 8, 20260.7052x1.1465x
Oct 9, 20260.7131x1.1534x
Oct 12, 20260.7266x1.1527x
Oct 13, 20260.7229x1.1526x
Oct 14, 20260.7201x1.1401x
Oct 15, 20260.7395x1.1434x
Oct 16, 20260.7393x1.1307x
Oct 19, 20260.7446x1.1357x
Oct 20, 20260.7501x1.1393x
Oct 21, 20260.7343x1.1453x
Oct 22, 20260.7546x1.1318x
Oct 23, 20260.7573x1.1258x
Oct 26, 20260.7593x1.1338x
Oct 27, 20260.7508x1.1402x
Oct 28, 20260.7426x1.1441x
Nov 5, 20260.8001x1.0859x
Nov 9, 20260.7886x1.1151x
Nov 10, 20260.7852x1.1110x
Nov 11, 20260.7840x1.1256x
Nov 12, 20260.7710x1.1216x
Nov 13, 20260.7756x1.1176x
Nov 16, 20260.7681x1.0962x
Nov 17, 20260.7623x1.0851x
Nov 18, 20260.7607x1.0817x
Nov 19, 20260.7473x1.0605x
Nov 20, 20260.7350x1.0219x

Themes and category

Longevity HealthcareLongevity & HealthcareQuality

Methodology and caveats

QuantLink fetches this idea from the live FastAPI ideas endpoints and renders the returned title, thesis, holdings, themes, benchmark, and tearsheet fields directly. Missing fields are left unavailable rather than fabricated.

Holdings are a curated model basket. They are not 13F filings, not insider filings, not adviser holdings, and not a claim that any person or fund owns the basket.

Backtested performance depends on the returned basket weights, benchmark, rebalancing assumptions, available price history, and calculation choices in the tearsheet endpoint. Backtests can differ materially from live results and do not include every cost, tax, capacity, liquidity, or execution constraint an investor may face.

Equal-weight and target-weight baskets can drift between rebalance points. Rebalancing can increase turnover, and concentrated thematic baskets can have higher drawdowns than a broad market benchmark.

Frequently asked questions

Research the stocks behind this idea

Use QuantLink's screener and company pages to inspect fundamentals, valuation, and market data after reviewing the public thesis.

Related links

QuantLink is a research tool, not investment advice. This page shows a curated model basket and backtested performance, not a filed portfolio, fund return, or recommendation to buy or sell securities.